{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:13:41Z","timestamp":1786119221762,"version":"build-2736575974"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1097\/cad.0b013e3283043585","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T13:28:45Z","timestamp":1236259725000},"page":"733-737","source":"Crossref","is-referenced-by-count":27,"title":["Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer"],"prefix":"10.1097","volume":"19","author":[{"given":"David","family":"Rossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Baldelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Casadei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano Luzi","family":"Fedeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Alessandroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Giordani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Ceccolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Graziano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Catalano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210203","first-page":"1651","article-title":"Cancer: principles and practice of oncology. 6th ed","author":"Winer","year":"2001"},{"issue":"12","key":"R2-10-20210203","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1053\/sonc.2001.26436","article-title":"Liposomal anthracyclines for breast cancer","volume":"28","author":"Sparano","year":"2001","journal-title":"Semin Oncol"},{"issue":"4","key":"R3-10-20210203","first-page":"1","article-title":"Anthracyclines in the treatment of cancer: an overview","volume":"54","author":"Hortobagyi","year":"1997","journal-title":"Drugs"},{"key":"R4-10-20210203","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1006\/gyno.2001.6355","article-title":"Antharcyclines in the treatment of gynaecologic malignancies","volume":"85","author":"Maluf","year":"2002","journal-title":"Gynecol Oncol"},{"key":"R5-10-20210203","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1200\/JCO.2002.11.005","article-title":"Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial","volume":"20","author":"Biganzoli","year":"2002","journal-title":"J Clin Oncol"},{"key":"R6-10-20210203","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.1200\/JCO.2004.02.122","article-title":"Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer","volume":"22","author":"Dieras","year":"2004","journal-title":"J Clin Oncol"},{"key":"R7-10-20210203","first-page":"3360","article-title":"A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer","volume":"8","author":"Giordano","year":"2002","journal-title":"Clin Cancer Res"},{"key":"R8-10-20210203","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/oxfordjournals.annonc.a010717","article-title":"Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic","volume":"7","author":"Gehl","year":"1996","journal-title":"Ann Oncol"},{"key":"R9-10-20210203","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1200\/JCO.1995.13.7.1777","article-title":"Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies","volume":"13","author":"Uziely","year":"1995","journal-title":"J Clin Oncol"},{"key":"R10-10-20210203","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1200\/JCO.2001.19.5.1444","article-title":"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer","volume":"19","author":"Batist","year":"2001","journal-title":"J Clin Oncol"},{"key":"R11-10-20210203","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.1997.15.10.3185","article-title":"Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin. Results of a mulicenter phase II trial","volume":"15","author":"Ranson","year":"1997","journal-title":"J Clin Oncol"},{"key":"R12-10-20210203","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.1998.16.10.3353","article-title":"Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer","volume":"16","author":"Seidman","year":"1998","journal-title":"J Clin Oncol"},{"key":"R13-10-20210203","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/00001813-200010000-00002","article-title":"Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer","volume":"11","author":"Schwonzen","year":"2000","journal-title":"Anticancer Drugs"},{"key":"R14-10-20210203","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1016\/S0959-8049(02)00168-5","article-title":"Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours","volume":"38","author":"Androulakis","year":"2002","journal-title":"Eur J Cancer"},{"key":"R15-10-20210203","first-page":"206","article-title":"A phase I study of paclitaxel in combination with pegylated liposomal doxorubicin (PLD) as second-line chemotherapy in metastatic breast cancer (MBC)","volume":"22","author":"Lortholary","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"R16-10-20210203","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000059568","article-title":"Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors","volume":"62","author":"Mavroudis","year":"2002","journal-title":"Oncology"},{"key":"R17-10-20210203","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1093\/annonc\/mdf284","article-title":"Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group","volume":"13","author":"Gogas","year":"2002","journal-title":"Ann Oncol"},{"key":"R18-10-20210203","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"R19-10-20210203","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1023\/A:1013574328938","article-title":"Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors","volume":"12","author":"Eng","year":"2001","journal-title":"Ann Oncol"},{"issue":"2","key":"R20-10-20210203","first-page":"74","article-title":"Neo-adjuvant therapy of breast cancer","volume":"16","author":"Bafaloukos","year":"2005","journal-title":"Ann Oncol"},{"issue":"17","key":"R21-10-20210203","first-page":"10","article-title":"Pilot study of primary chemotherapy with doxorubicin plus paclitaxel in women with locally advanced or operable breast cancer","volume":"24","author":"Moliterni","year":"1997","journal-title":"Semin Oncol"},{"key":"R22-10-20210203","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S0959-8049(01)00050-8","article-title":"Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL\/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by EORTC Soft Tissue and Bone Sarcoma Group","volume":"37","author":"Judson","year":"2001","journal-title":"Eur J Cancer"},{"key":"R23-10-20210203","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/annonc\/mdf157","article-title":"EORTC 10968: a phase I trial and clinical pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer","volume":"13","author":"Hamilton","year":"2002","journal-title":"Ann Oncol"},{"key":"R25-10-20210203","first-page":"70","article-title":"Phase II study with combination of pegylated liposomal doxorubicin (Caelyx) and cyclophosphamide (CC) in locally advanced breast cancer (LABC)","volume":"21","author":"Srimuninnimit","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"R26-10-20210203","first-page":"35a","article-title":"Weekly paclitaxel followed by FAC as primary systemic chemotherapy of operable breast cancer improves pathologic complete remission (pCR) rates when compared to every 3-week (Q3wk) P therapy (tx) followed by FAC-final results of a prospective phase III randomized trial","volume":"21","author":"Green","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"R27-10-20210203","doi-asserted-by":"crossref","first-page":"8715","DOI":"10.1158\/1078-0432.CCR-05-0539","article-title":"Feasibility and tolerability of sequential doxorubicin\/paclitaxel followed by cyclophosphamide, methotrexate, and fluoruracil and its effects on tumor response as preoperative therapy","volume":"11","author":"Gianni","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R29-10-20210203","first-page":"96a","article-title":"The use of neoadjuvant Doxil in the treatment of stage III breast cancer","volume":"18","author":"Hurley","year":"1999","journal-title":"Proc Soc Am Clin Oncol"},{"key":"R30-10-20210203","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1158\/1078-0432.CCR-06-1345","article-title":"Neoadjuvant therapy with paclitaxel followed by 5-fluouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2 \u2013 positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen","volume":"13","author":"Buzdar","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R31-10-20210203","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1200\/JCO.2005.03.8331","article-title":"Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial","volume":"24","author":"Chia","year":"2006","journal-title":"J Clin Oncol"},{"key":"R32-10-20210203","first-page":"18s","article-title":"Paclitaxel, pegylated liposomal doxorubicin (PLD) and trastuzumab as first line chemotherapy in HER-2\/Neu positive (+) metastatic breast cancer patients","volume":"24","author":"Karabelis","year":"2006","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CAD.0b013e3283043585","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:01:39Z","timestamp":1786039299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001813-200808000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e3283043585","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}